This paper is a contribution to the debate about whether regulations that ban insurance companies from access to individuals’ genetic tests may lead in the near to medium term future to substantial adverse selection costs. We choose the specific possibility of widespread knowledge based on genetic testing for the so-called breast cancer (BRCA1/2) genes. We use a data set including economic, demographic, and relevant family background information to simulate the market for 10-year term life insurance targeted at women aged 35 to 39. Using standard welfare economic analysis for various information and regulatory scenarios concerning genetic test results, we find generally only modest adverse selection costs associated with such a regulatory ban. However, for family background groups which are at high risk for carrying one of the BRCA1/2 genes, the efficiency cost of adverse selection may be significant especially if a large fraction of women within such groups were to obtain genetic test results. These results, therefore, suggest some caution in developing regulations which protect individuals’ genetic privacy.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
Publisher Info
Paper provided by University of Guelph, Department of Economics in its series Working Papers with number
0505.
References listed on IDEAS Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.: